Skip to content

Efficacy of "American Sunflowers Potato" on Improvement of type2 Diabetes and its Safety.

Efficacy of "American Sunflowers Potato" on Improvement of type2 Diabetes and its Safety. - ASPMD trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000016161
Enrollment
14
Registered
2015-01-15
Start date
2014-12-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes

Interventions

Mild diabetic patients (n=14) eat ASP supplements before every meal during 12 weeks.

Sponsors

IMEQRD Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. 23<=BMI<30 2. Patients with HbA1c(6.0%-8.0%) who have received a diagnosis of diabetes and received either diet, exercise or drug therapy. Alternatively, Patient who have never received a diagnosis of diabetes with corresponding to the items below - HbA1c value:6.5%-8.0% -Fasting glucose:126mg/dl or more (or more at any time blood glucose level 200mg / dl) 3. Patients planned to maintain the dose of current therapies and therapeutic agents during the study period

Exclusion criteria

Exclusion criteria: 1.Patients with a history of heart failure, such as myocardial infarction and 2.Exclude by disease, etc. (Liver disease, kidney disease, who complications of cerebrovascular disease corresponds to grade 3 of severity classification criteria of side effects such as drug) 3.Patients requiring the use of insulin in the treatment of primary disease 4.Use supplements that contain the same components as American San Flowers potato Use supplements blood sugar reducing effect is assumed 5.Patients with allergy symptoms caused by drugs and test article-related food 6. pregnant and lactating. or a person likely to become pregnant during the study period

Design outcomes

Primary

MeasureTime frame
HbA1c Insulin Fasting blood sugar HOMA-R

Countries

Japan

Contacts

Public ContactYoshitada Hira

IMEQRD Co., Ltd. Planning and Sales Department

clinical-trial@imeqrd.co.jp03-6704-5968

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026